Pralatrexate: all 35 studies that test it

Page 1 of 1. Open to participants first (3), then studies with results posted, then the rest; newest registration first within each.

• Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell LymphomaNot yet recruitingNCT07691450Phase 1
• Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin LymphomaRecruitingNCT07225985Phase 1/2
• Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic ImpairmentRecruitingNCT07036133Phase 1
• Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell LymphomasActive, not recruitingNCT03598998Phase 1/2Results posted
• A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCLCompletedNCT03349333Phase 3Results posted
• Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid MalignanciesTerminatedNCT01947140Phase 1/2Results posted
• Pralatrexate vs Observation Following CHOP-based Chemotherapy in Undiagnosed Peripheral T-cell Lymphoma PatientsTerminatedNCT01420679Phase 3Results posted
• Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin LymphomaCompletedNCT01336933Phase 2Results posted
• Pralatrexate and Fluorouracil in Treating Patients With Recurrent Solid TumorsCompletedNCT01206465Phase 1Results posted
• Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal CancerCompletedNCT01188876Phase 1/2Results posted
• Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)CompletedNCT01183065Phase 2Results posted
• Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction CancerCompletedNCT01178944Phase 2Results posted
• Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based TherapyCompletedNCT01129206Phase 2Results posted
• Study of Pralatrexate in Female Patients With Previously-treated Breast CancerCompletedNCT01118624Phase 2Results posted
• Study of Pralatrexate to Treat Participants With Relapsed or Refractory B-cell Non-Hodgkin's LymphomaCompletedNCT00998946Phase 2Results posted
• Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary BladderCompletedNCT00722553Phase 2Results posted
• Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based TreatmentCompletedNCT00606502Phase 2Results posted
• Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative MalignanciesCompletedNCT00481871Phase 1/2Results posted
• Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell LymphomaCompletedNCT00364923Phase 2Results posted
• 10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's LymphomaCompletedNCT00052442Phase 1/2Results posted
• To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCLActive, not recruitingNCT06072131Phase 3
• Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCLWithdrawnNCT03355768Phase 3
• Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCLActive, not recruitingNCT03240211Phase 1
• Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for LymphomaStatus unknownNCT03161223Phase 1/2
• A Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior TherapyStatus unknownNCT03150602Phase 4
• A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL)CompletedNCT02594267Phase 1
• Phase II Study of Folotyn With Leucovorin to Prevent/Reduce Mucositis in Patients With Hematological MalignanciesCompletedNCT02106650Phase 2
• Phase I/II Clinical Study of Pralatrexate in Japanese Patients With Relapsed or Refractory Peripheral T-cell LymphomaCompletedNCT02013362Phase 1/2
• Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn®WithdrawnNCT01820091Phase 1
• Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving FolotynWithdrawnNCT01789723Phase 1
• Erlotinib in Combination With Pralatrexate in Advanced MalignanciesCompletedNCT01532011Phase 1
• Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell LymphomaCompletedNCT01134341Phase 1
• Phase I Bortezomib (VELCADE) in Combo With Pralatrexate in Relapsed/Refractory MMCompletedNCT01114282Phase 1
• Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell LymphomaCompletedNCT00554827Phase 1
• 10-Propargyl-10-Deazaaminopterin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung CancerCompletedNCT00004238Phase 2

← Pralatrexate overview